Business Case

Evaluated 10 potential indications for a clinical-stage Biotech seeking to prioritize the clinical path to market and potential return of two assets

Our mid-sized biotech client commercialized its first product and subsequently filled a robust pipeline of solid tumor-targeting agents. Two leading agents had broad applicability with novel MOAs and demonstrated tolerability. Our client asked LSC to help understand the clinical potential and path forward for ten potential indications. LSC prepared factbook dossiers for each indication, sizing the market and identifying the net potential market for each therapy in context of competition and realistic line of therapy. Target product profiles (TPPs) were developed for each indication and tested in the market to guide the clinical path to market. LSC workshopped with the cross-functional client team to align on the most attractive clinical pathways to market.